An Update on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Small Animals

Veterinary Clinics of North America - Small Animal Practice

Volumn 38, Issue 6, 2008, Pages 1243-1266

  Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Analgesic drugs; Anti inflammatory drugs; Arthritis; Cats; COX 1; Dogs; NSAIDs; Pain

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANAFEN; CARPROFEN; CELECOXIB; COCODAMOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DERACOXIB; DIPYRONE; ETODOLAC; ETOGESIC; FIROCOXIB; FLUNIXIN; FLUOXETINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; KETOPROFEN; MECLOFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PREVICOX; ROFECOXIB; SELEGILINE; TEPOXALIN; TOLFENAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZUBRIN;

CAT; DOG; DRUG APPROVAL; DRUG CHOICE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; NONHUMAN; OFF LABEL DRUG USE; OSTEOARTHRITIS; PRACTICE GUIDELINE; PUBLICATION; RECOMMENDED DRUG DOSE; REVIEW; UNITED STATES; VETERINARY MEDICINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CAT DISEASES; CATS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; OSTEOARTHRITIS; PHENYLBUTAZONE; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 54149104431     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2008.09.002     Document Type: Review

References (112)

1. Papich M.G. Saunders handbook of veterinary drugs. 2nd edition (2007), Elsevier-Saunders Co, St. Louis (MO)
2. Papich M.G. Pharmacologic considerations for opiate analgesic and nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract 30 (2000) 815-837
3. Bergh M.S., and Budsgerg S.C. The COXIB NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 19 (2005) 633-643
4. Lees P., Landoni M.F., Giraudel J., et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 27 6 (2004) 479-490
5. Lascelles B.D.X., McFarland J.M., and Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Vet Ther 6 3 (2005) 237-250
6. Lascelles B.D.X., Court M.H., Hardie E.M., et al. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anaesth Analg 34 (2007) 228-250
7. Vane J.R., and Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44 (1995) 1-10
8. Laneuville O., Breuer D.K., DeWitt D.L., et al. Differential inhibition of human prostaglandin endoperoxide synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271 (1994) 927-934
9. Meade E.A., Smith W.L., and DeWitt D.L. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci 714 (1994) 136-142
10. Wooten J.G., Blikslager A.T., Ryan K.A., et al. Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. Am J Vet Res 69 4 (2008) 457-464
11. Konturek S.J., Konturek P.C., and Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 56 Suppl 5 (2005) 5-31
12. Punke J.P., Speas A.L., Reynolds L.R., et al. Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs. Am J Vet Res 69 9 (2008) 1203-1209
13. Bertolini A., Ottani A., and Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 44 (2001) 437-450
14. Flower R.J., and Vane J.R. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 240 5381 (1972) 410-411
15. Chandrasekharan N.V., Dai H., Roos K.L., et al. A cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 99 21 (2002) 13926-13931 (with commentary in Proc Natl Acad Sci U S A. 99(21):13371-13373, 2002)
16. Davies N.M., Good R.L., Roupe K.A., et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?-not as easy as 1, 2, 3. J Pharm Pharm Sci 7 2 (2004) 217-226
17. Aronoff D.M., Oates J.A., and Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 79 (2005) 9-19
18. Kis B., Snipes J.A., and Busija D.W. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 315 1 (2005) 1-7
19. Gierse J.K., Staten N.R., Casperson G.F., et al. Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2. Vet Ther 3 (2002) 270-280
20. McCann M.E., Andersen D.R., Zhang D., et al. In vitro effects and in vivo efficacy of a novel cyclo-oxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 65 (2004) 503-512
21. Ricketts A.P., Lundy K.M., and Seibel S.B. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 59 (1998) 1441-1446
22. Kay-Mugford P., Benn S.J., LaMarre J., et al. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 61 (2000) 802-810
23. Wilson J.E., Chandrasekharan N.V., Westover K.D., et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 65 (2004) 810-818
24. McKellar Q.A., Delatour P., and Lees P. Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. J Vet Pharmacol Ther 17 (1994) 447-454
25. Glaser K.B. Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (lodine). Inflammopharmacology 3 (1995) 335-345
26. Lees P. Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology 11 (2003) 385-399
27. Patrignani P., Panara M.R., Greco A., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271 3 (1994) 1705-1712
28. Blain H., Boileau C., Lapicque F., et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53 3 (2002) 255-265
29. Hinz B., and Brune K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 29 8 (2008) 391-397
30. Lees P., Giraudel J., Landoni M.F., et al. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther 27 6 (2004) 491-502
31. Giraudel J.M., Diquelou A., Laroute V., et al. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 146 5 (2005) 642-653
32. Giraudel J.M., Diquelou A., Lees P., et al. Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs. J Vet Pharmacol Ther 28 3 (2005) 275-285
33. Borer L.R., Peel J.E., Seewald W., et al. Effect of carprofen, etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis. Am J Vet Res 64 (2003) 1429-1437
34. Jones C.J., Streppa H.K., Harmon B.G., et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 63 (2002) 1527-1531
35. Sessions J.K., Reynolds L.R., and Budsberg S.C. In vivo effects of carprofen, deracoxib, and etodolac on prostanoids production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 66 (2005) 812-817
36. Bryant C.E., Farnfield B.A., and Janicke H.J. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res 64 (2003) 211-215
37. FitzGerald G.A., and Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
38. McCann M.E., Rickes E.L., Hora D.F., et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res 66 (2005) 1278-1284
39. Peterson W.L., and Cryer B. COX-1-sparing NSAIDs-is the enthusiasm justified?. J Am Med Assoc 282 (1999) 1961-1963 [see also pages 1921 and 1929 of this issue.].
40. Lascelles B.D.X., Blikslager A.T., Fox S.M., et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 227 (2005) 1112-1117
41. Drazen J.M. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med 352 (2005) 1131-1132
42. Malhotra S., Shafiq N., and Pandhi P. COX-2 inhibitors: a CLASS act, or just VIGOR-ously promoted. MedGenMed 6 1 (2004). Available at: www.medscape.com
43. Psaty B.M., and Furberg C.D. COX-2 inhibitors-lessons in drug safety. N Engl J Med 352 (2005) 1133-1135
44. Jüni P., Rutjes A.W.S., and Dieppe P.A. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. Br Med J 324 (2002) 1287-1288
45. Rainsford K.D. The ever-emerging anti-inflammatories. Have there been any real advances?. J Physiol 95 (2001) 11-19
46. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
47. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
48. FitzGerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
49. Topol E.J. Failing the public health-rofecoxib, Merck and the FDA. N Engl J Med 351 (2004) 1707-1709
50. Eisenberg R.S. Learning the value of drugs-is rofecoxib a regulatory success story?. N Engl J Med 352 (2005) 1285-1287
51. Okie S. Raising the safety bar-the FDA's Coxib meeting. N Engl J Med 345 (2005) 1283-1285
52. Trang T., McNaull B., Quirion R., et al. Involvement of spinal lipoxygenase metabolites in hyperalgesia and opiate tolerance. European Journal of Pharmacology 491 (2004) 21-30
53. Moreau M., Daminet S., Martel-Pelletier J., et al. Superiority of the gastrointestinal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor in dogs. J Vet Pharmacol Ther 28 (2005) 81-86
54. Boston S.E., Moens N.M., Kruth S.A., et al. Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs. Am J Vet Res 64 11 (2003) 1369-1375
55. Narita T., Sato R., Motoishi K., et al. The interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs. J Vet Med Sci 69 4 (2007) 353-363
56. Agnello K.A., Reynolds L.R., and Budsberg S.C. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis. Am J Vet Res 66 6 (2005) 966-972
57. Hjelle J.J., and Grauer G.F. Acetaminophen-induced toxicosis in dogs and cats. J Am Vet Med Assoc 188 (1986) 742-746
58. Bradley J.D., Brandt K.D., Katz B.P., et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325 (1991) 87-91
59. Mburu D.N., Mbugua L.A., Skoglund L.A., et al. Effects of paracetamol (acetaminophen) and acetylsalicylic acid on the post-operative course after experimental orthopaedic surgery in dogs. J Vet Pharmacol Ther 11 (1988) 163-171
60. Mburu D.N. Evaluation of the anti-inflammatory effects of a low-dose of acetaminophen following surgery in dogs. J Vet Pharmacol Ther 14 (1991) 109-111
61. Savides M.C., Oehme F.W., Nash S.L., et al. The toxicity and biotransformation of single doses of acetaminophen in dogs and cats. Toxicol Appl Pharmacol 74 (1984) 26-34
62. Hinz B., Cheremina O., and Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22 2 (2007) 383-390
63. Pickering G., Esteve V., Loriot M.-A., et al. Acetaminophen reinforces descending inhibitory pain pathways. Clin Pharmacol Ther 84 1 (2008) 47-51
64. Mathews K.A. Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J 37 (1996) 539-545
65. Dowers K.L., Uhrig S.R., Mama K.R., et al. Effect of short-term sequential administration of nonsteroidal anti-inflammatory drugs on the stomach and proximal portion of the duodenum in healthy dogs. Am J Vet Res 67 10 (2006) 1794-1801
66. Galbraith E.A., and McKellar Q.A. Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Vet Rec 128 (1991) 561-565
67. Knapp D.W., Richardson R.C., Chan T.C.K., et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8 4 (1994) 273-278
68. Schmidt B.R., Glickman N.W., DeNicola D.B., et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 218 (2001) 1783-1786
69. Brune K. Safety of anti-inflammatory treatment-new ways of thinking. Rheumatology 43 Suppl 1 (2004) i16-i20
70. Wallace J.L., and Fiorucci S. A magic bullet for mucosal protection.and aspirin is the trigger!. Trends Pharmacol Sci 24 7 (2003) 323-6
71. Fiorucci S., de Lima Jr. O.M., Mencarelli A., et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123 5 (2002) 1598-1606
72. Souza M.H., de Lima Jr. O.M., Zamuner S.R., et al. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol 285 1 (2003) G54-G61
73. Brzozowski T., Konturek P.C., Konturek S.J., et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 56 Suppl 5 (2005) 33-55
74. Taylor L.A., and Crawford L.M. Aspirin-induced gastrointestinal lesions in dogs. J Am Vet Med Assoc 152 6 (1968) 617-619
75. Sennello K.A., and Leib M.S. Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. J Vet Intern Med 20 (2006) 1291-1296
76. Raekallio M.R., Hielm-Björkman A.K., Kejonen J., et al. Evaluation of adverse effects of long-term orally administered carprofen in dogs. J Am Vet Med Assoc 228 6 (2006) 876-880
77. Wallace J.L., Wallace J.L., Zamuner S.R., et al. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol 286 1 (2004) G76-G81
78. Ryan W.G., Moldave K., and Carithers D. Switching NSAIDs in practice: insights from the Previcox (firocoxib) experience trial. Vet Ther 8 4 (2007) 263-271
79. Whittle B.J. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 500 1-3 (2004) 427-439
80. Lee Y.S., Kim H., Wu T.X., et al. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 79 5 (2006) 407-418
81. Forsyth S.F., Guilford W.G., Haslett S.J., et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 39 (1998) 421-424
82. Reimer M.E., Johnston S.A., Leib M.S., et al. The gastrointestinal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med 13 (1999) 472-477
83. Doig P.A., Purbrick K.A., Hare J.E., et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 41 4 (2000) 296-300
84. Enberg T.B., Braun L.D., and Kuzma A.B. Gastrointestinal perforation in five dogs associated with the administration of meloxicam. Journal of Veterinary Emergency and Critical Care 16 (2006) 34-43
85. Mathews K.A., Doherty T., Dyson D.H., et al. Nephrotoxicity in dogs associated with methoxyflurane anesthesia and flunixin meglumine analgesia. Can Vet J 31 (1990) 766-771
86. Lobetti R.G., and Joubert K.E. Effect of administration of nonsteroidal anti-inflammatory drugs before surgery on renal function in clinically normal dogs. Am J Vet Res 61 (2000) 1501-1506
87. Gambaro G., and Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclo-oxygenase inhibitors. J Intern Med 253 (2003) 643-652
88. Rossat J., Maillard M., Nussberger J.U., et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66 (1999) 76-84
89. Boström I.M., Nyman G.C., Lord P.F., et al. Effects of carprofen on renal function and results of serum biochemical and hematologic analyses in anesthetized dogs that had low blood pressure during anesthesia. Am J Vet Res 63 (2002) 712-721
90. Crandell D.E., Mathews K.A., and Dyson D.H. Effect of meloxicam and carprofen on renal function when administered to healthy dogs prior to anesthesia and painful stimulation. Am J Vet Res 65 10 (2004) 1384-1390
91. Frendin J.H., Boström I.M., Kampa N., et al. Effects of carprofen on renal function during medetomidine-propofol-isoflurane anesthesia in dogs. Am J Vet Res 67 12 (2006) 1967-1973
92. Ko J.C.H., Miyabiyashi T., Mandsager R.E., et al. Renal effects of carprofen administered to healthy dogs anesthetized with propofol and isoflurane. J Am Vet Med Assoc 217 (2000) 346-349
93. Bergmann H.M.L., Nolte I.J.A., and Kramer S. Effects of preoperative administration of carprofen on renal function and hemostasis in dogs undergoing surgery for fracture repair. Am J Vet Res 66 (2005) 1356-1363
94. Fusellier M., Desfontis J.-C., LeRoux A., et al. Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs. Journal of Veterinary Pharmacology and Therapeutics 31 (2008) 150-155
95. Boström I.M., Nyman G., Hoppe A., et al. Effects of meloxicam on renal function in dogs with hypotension during anaesthesia. Vet Anaesth Analg 33 1 (2006) 62-69
96. Kay-Mugford P.A., Grimm K.A., Weingarten A.J., et al. Effect of preoperative administration of tepoxalin on hemostasis and hepatic and renal function in dogs. Vet Ther 5 (2004) 120-127
97. Luna S.P., Basílio A.C., Steagall P.V., et al. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 68 3 (2007) 258-264
98. de Broe M.E., and Elseviers M.M. Analgesic nephropathy. N Engl J Med 338 (1998) 446-452
99. Loboz K.K., and Shenfield G.M. Drug combinations and impaired renal function-the triple whammy. Br J Clin Pharmacol 59 (2005) 239-243
100. Lefebvre H.P., and Toutain P.L. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther 27 5 (2004) 265-281
101. Gunew M.N., Menrath V.H., and Marshall R.D. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg 10 3 (2008) 235-241
102. McCann M.E., Rickes E.L., Hora D.F., et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res 66 (2005) 01278-01284
103. Lee W.M. Drug induced hepatotoxicity. N Engl J Med 349 (2003) 474-485
104. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 105 Suppl 5A (1998) 17S-21S
105. Tolman K.G. Hepatotoxicity of non-narcotic analgesics. Am J Med 105 Suppl 1B (1998) 13S-7S
106. Vasseur P.B., Johnson A.L., Budsberg S.C., et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal antiinflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 206 (1995) 807-811
107. MacPhail C.M., Lappin M.R., Meyer D.J., et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 212 (1998) 1895-1901
108. Hickford F.H., Barr S.C., and Erb H.N. Effect of carprofen on hemostatic variables in dogs. Am J Vet Res 62 10 (2001) 1642-1646
109. Lascelles B.D.X., Cripps P.J., Jones A., et al. Efficacy and kinetics of carprofen, administered preoperatively or postoperatively, for the prevention of pain in dogs undergoing ovariohysterectomy. Vet Surg 27 (1998) 568-582
110. Budsberg S.C., Cross A.R., Quandt J.E., et al. Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs. Am J Vet Res 63 11 (2002) 1557-1563
111. Caulkett N., Read M., Fowler D., et al. A comparison of the analgesic effects of butorphanol with those of meloxicam after effective ovariohysterectomy in dogs. Can Vet J 44 7 (2003) 565-570
112. Mathews K.A., Pettifer G., Foster R., et al. Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. AM J Ver Res 62 6 (2001) 882-888